Biotech Investment Analyst — Drug Asset & Company Assessment
Mercor
$120 – $200/hour · as listed
Biotech Investment Analyst — Drug Asset & Company Assessment
This remote role involves creating and evaluating assessment rubrics for commercial drugs and drug-development programs. You'll work with a biotech and pharma research team on expert human-evaluation tasks, developing frameworks that analyze drug assets and company potential. The work suits advanced professionals with investment analysis experience in biotech or pharma, particularly those with specialist-fund backgrounds who can apply deep domain knowledge to structured evaluation.
This is a part-time position available to US-based professionals, offered through the Mercor platform at $120–$200 per hour. The initial engagement is a paid pilot with potential to expand as the project scales. Expect around 15 hours per week. Strong writing skills and STEM expertise are essential for producing clear, rigorous assessment criteria.
From the listing: Mercor marketplace · part-time · 15h/week. Mercor is partnering with a biotech and pharma research team on expert human-evaluation work — creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We're seeking a biotech investment analyst (specialist-fund background) for a paid pilot, with the potential to continue as the work scales. Responsibilities - Create and critique rubrics that analyze comme
Applications are completed on the listing’s own site. Pay is shown as posted by the source (“as listed”) or the aggregator’s estimate where marked — offers and availability change, and individual results vary.
Want help getting selected — and finding the best-paid work for your country? See how membership works →